Alnylam Pharma (NASDAQ: ALNY) 30-day option implied volatility is at 42; compared to its 52-week range of 33 to 408 as share price up 38% to $229.30 after reports results from its HELIOS-B Phase 3 study of vutrisiran. July 105 puts and 110 puts, September 85 puts and January 260 calls active at $13.20.